<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206982</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/08</org_study_id>
    <nct_id>NCT04206982</nct_id>
  </id_info>
  <brief_title>MARSHALL PLAN Vs. Pulmonary Veins Isolation Monocentric Trial</brief_title>
  <acronym>PLAN-MARSHALL</acronym>
  <official_title>MARSHALL Bundles Elimination, Pulmonary Veins Isolation and Lines Completion for ANatomical Ablation of Persistent Atrial Fibrillation Versus Pulmonary Veins Isolation: The MARSHALL PLAN Monocentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In ablation strategy for persistent Atrial Fibrillation (PsAF), ablation limited to Pulmonary&#xD;
      Vein (PV) isolation is the most straightforward approach but the result give only 50% of&#xD;
      arrhythmia free follow-up. Substrate modification strategies have failed to demonstrate their&#xD;
      superiority with variable reported success rate. The Marshall network is a highly&#xD;
      arrhythmogenic structure that has not been incorporated in current ablation strategies. The&#xD;
      investigators sought to investigate a new ablation strategy that target systematically the&#xD;
      vein of Marshall by ethanol infusion. This step is integrated in a new ablation strategy&#xD;
      consisting in a global anatomical substrate based ablation including PV isolation and left&#xD;
      atrial linear ablation (Marshall-Plan).&#xD;
&#xD;
      The main objective of this study is to compare the 12 month freedom from any arrhythmia&#xD;
      (Atrial Fibrillation (AF)/Atrial Tachycardia (AT)) between the Marshall-Plan approach and the&#xD;
      PV isolation approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ablation strategy for persistent AF besides pulmonary vein isolation remains controversial.&#xD;
      Indeed, two approaches have prevailed over the past two decades &quot;cox-maze&quot; strategy and&#xD;
      mapping of the left atrium but both methods have failed to decrease AF recurrences (as shown&#xD;
      by the clinical trial STAR AF 2). Two studies have demonstrated that the ligament of Marshall&#xD;
      (LOM) could be the source of focal activities, the substrate of reentries and a strong&#xD;
      parasympathetic modulator. For these reasons, LOM may represent a major target in AF&#xD;
      treatment besides PV isolation. Nevertheless, conventional ablation techniques do not ensure&#xD;
      the complete destruction of Marshall's musculature and parasympathetic ganglia that surround&#xD;
      it, largely isolated by a sheath of adipose tissue. To overcome this technical limitation,&#xD;
      LOM elimination can be achieved by alcohol injection into the vein of Marshall.The&#xD;
      investigator innovative approach called Marshall Plan will then consists in 3 steps: 1) the&#xD;
      destruction of Marshall bundles by ethanol infusion followed by the ablation of the distal&#xD;
      Coronary Sinus (CS) bundles, the ridge and the saddle; 2) the standard PV isolation; 3) and&#xD;
      finally ablation of the mitral line, the roof and of the cavo-tricuspid isthmus, main causes&#xD;
      of recurrence in atrial flutter.&#xD;
&#xD;
      Before ablation procedure patients will be randomized in 2 arms: Marshall Plan (treatment&#xD;
      arm) or pulmonary vein isolation (control arm). Patients will be followed at 3, 6, 9 and 12&#xD;
      months in-office visits or hospitalization. Patients will have different tests:&#xD;
      electrocardiogram (ECG), cardiac echography, stress test, 24hours Holter and transtelephonic&#xD;
      ECG monitor with weekly transmitted ECG and at any time in case of symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Marshall Plan is a prospective randomized, parallel-group, monocentric clinical trial of superiority.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds with or without antiarrhythmic medications.</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post ablation, at 12 months with or without antiarrhythmic medications. Recurrences will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF greater than 30 seconds</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence rate (percentage) of AF greater than 30 seconds after the blanking period of 3-months post procedure at 12 months. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds without antiarrhythmic medications</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post ablation, at 12 months without antiarrhythmic medications. Recurrences will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients under antiarrhythmic medications</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with repeat procedures</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of periprocedural complications</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of transient ischemic attack or stroke, cardiac tamponade, atrio-oesophageal fistula, pericarditis, complications at access site (hematoma, arteriovenous fistula, pseudoaneurysm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF discontinuation rate during procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of AF discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-procedure AF / AT inducibility rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of per-procedure AF / AT inducibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral line block rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of mitral line block according to consensus block criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency duration necessary for pulmonary veins isolation</measure>
    <time_frame>12 months</time_frame>
    <description>Duration measured in seconds</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Marshall Plan arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Destruction of Marshall bundles</intervention_name>
    <description>Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary veins isolation</intervention_name>
    <description>Achievement of a wide disconnection of the right and left pulmonary veins.</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
    <arm_group_label>Pulmonary vein isolation arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Linear ablation in the left and right atria</intervention_name>
    <description>Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years of both genders&#xD;
&#xD;
          -  Suitable candidate for catheter non-emergent mapping and ablation of atrial&#xD;
             fibrillation defined as:&#xD;
&#xD;
               -  History of symptomatic persistent atrial fibrillation in the past year documented&#xD;
                  by ECG AND&#xD;
&#xD;
               -  Treatment failure by at least one class of anti-arrhythmic medications (I-IV)&#xD;
                  (intolerance or recurrence of symptomatic AF)&#xD;
&#xD;
          -  Patient affiliated or beneficiary of social security scheme&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant and the principal&#xD;
             investigator (at least at the inclusion date and before all exams required for the&#xD;
             clinical research)&#xD;
&#xD;
          -  Effective contraception for women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Prior left atrial heart ablation procedure&#xD;
&#xD;
          -  Documented left atrial thrombus or another abnormality which precludes catheter&#xD;
             introduction&#xD;
&#xD;
          -  Contraindication to anticoagulation therapy (heparin, warfarin, or Novel Oral&#xD;
             Anticoagulant (NOAC)&#xD;
&#xD;
          -  Contraindication to iodinated contrast product XENETIX® (iobitridol hypersensitivity&#xD;
             or at one of these excipients, history of major immediate reaction or cutaneous&#xD;
             reaction to XENETIX® infusion, thyrotoxicosis)&#xD;
&#xD;
          -  Hypersensitivity to ethanol&#xD;
&#xD;
          -  Unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
          -  Myocardial infarction within 3 months prior to inclusion&#xD;
&#xD;
          -  Congenital heart disease, where the underlying abnormality increases the ablation risk&#xD;
&#xD;
          -  Pulmonary hypertension (pulmonary arterial hypertension &gt; 50 mmHg)&#xD;
&#xD;
          -  Severe uncontrolled systemic hypertension with systolic blood pressure (SBP) &gt; 200 mm&#xD;
             Hg within 30 days prior to inclusion&#xD;
&#xD;
          -  Severe bleeding, clotting or thrombotic disorder&#xD;
&#xD;
          -  Left atrial diameter &gt; 60 mm (parasternal view)&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy defined by a left ventricular septum thickness &gt; 1.5 cm&#xD;
&#xD;
          -  Pregnant, parturient or nursing women&#xD;
&#xD;
          -  Unable or unwilling to provide written informed consent&#xD;
&#xD;
          -  Patient detained by judicial or administrative order&#xD;
&#xD;
          -  Patient under psychiatric care&#xD;
&#xD;
          -  Patient admitted in a social or healthcare establishment for any purpose other than&#xD;
             the research&#xD;
&#xD;
          -  Subject to a legal protection order (guardianship, patient under legal protection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas DERVAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas DERVAL, MD</last_name>
    <phone>(0)5 57 65 64 71</phone>
    <phone_ext>+33</phone_ext>
    <email>nicolas.derval@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thimote LOOCK</last_name>
    <phone>(0)5 57 62 31 19</phone>
    <phone_ext>+33</phone_ext>
    <email>timothe.loock@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas DERVAL, MD</last_name>
      <phone>(0)5 57 65 64 71</phone>
      <phone_ext>+33</phone_ext>
      <email>nicolas.derval@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thimote LOOCK</last_name>
      <phone>(0)5 57 62 31 19</phone>
      <phone_ext>+33</phone_ext>
      <email>timothe.loock@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas DERVAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas PAMBRUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josselin DUCHATEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi CHAUVEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélèze HOCINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre JAIS, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain TIXIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Valderrábano M, Chen HR, Sidhu J, Rao L, Ling Y, Khoury DS. Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans. Circ Arrhythm Electrophysiol. 2009 Feb;2(1):50-6. doi: 10.1161/CIRCEP.108.818427.</citation>
    <PMID>19756206</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent atrial fibrillation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Ethanolisation</keyword>
  <keyword>Ligament of Marshall</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

